,20 A recently published study in the US, using the Surveillance Epidemiology, and End Results Program (SEER) database, reported that patients diagnosed after the treatment guidelines for cyclin-dependent kinase 4/6 inhibitor use were released (post-2015) had a 10% reduction (vs pre-2015) in the risk of breast cancer-specific death.20 The gene discussed is CDK4; the disease is breast cancer.